256 related articles for article (PubMed ID: 32419532)
21. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
[TBL] [Abstract][Full Text] [Related]
22. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
[TBL] [Abstract][Full Text] [Related]
23. Novel therapy for childhood acute lymphoblastic leukemia.
Santiago R; Vairy S; Sinnett D; Krajinovic M; Bittencourt H
Expert Opin Pharmacother; 2017 Aug; 18(11):1081-1099. PubMed ID: 28608730
[TBL] [Abstract][Full Text] [Related]
24. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group.
Stanulla M; Cario G; Meissner B; Schrauder A; Möricke A; Riehm H; Schrappe M
Blood Cells Mol Dis; 2007; 39(2):160-3. PubMed ID: 17532236
[TBL] [Abstract][Full Text] [Related]
25. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Ebeid EN; Kamel MM; Ali BA
J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
[TBL] [Abstract][Full Text] [Related]
26. Outcome and Prognostic Factors for
Lee JW; Kim SK; Jang PS; Chung NG; Jeong DC; Kim M; Cho B; Kim HK
Cancer Res Treat; 2017 Apr; 49(2):446-453. PubMed ID: 27506214
[TBL] [Abstract][Full Text] [Related]
27. Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults.
Mattison R; Stock W
Curr Hematol Malig Rep; 2008 Jul; 3(3):144-51. PubMed ID: 20425459
[TBL] [Abstract][Full Text] [Related]
28. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities.
Burkhardt B; Hermiston ML
Br J Haematol; 2019 Jun; 185(6):1158-1170. PubMed ID: 30809797
[TBL] [Abstract][Full Text] [Related]
29. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
30. Childhood and adolescent lymphoid and myeloid leukemia.
Pui CH; Schrappe M; Ribeiro RC; Niemeyer CM
Hematology Am Soc Hematol Educ Program; 2004; ():118-45. PubMed ID: 15561680
[TBL] [Abstract][Full Text] [Related]
31. SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Short NJ; Kantarjian H; Pui CH; Goldstone A; Jabbour E
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):439-446. PubMed ID: 29853276
[TBL] [Abstract][Full Text] [Related]
32. The Medical Research Council trials in adult acute lymphocytic leukemia.
Durrant IJ; Richards SM; Prentice HG; Goldstone AH
Hematol Oncol Clin North Am; 2000 Dec; 14(6):1327-52. PubMed ID: 11147226
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.
Issa GC; Kantarjian HM; Yin CC; Qiao W; Ravandi F; Thomas D; Short NJ; Sasaki K; Garcia-Manero G; Kadia TM; Cortes JE; Daver N; Borthakur G; Jain N; Konopleva M; Khouri I; Kebriaei P; Champlin RE; Pierce S; O'Brien SM; Jabbour E
Cancer; 2017 Feb; 123(3):459-467. PubMed ID: 27696391
[TBL] [Abstract][Full Text] [Related]
34. Second neoplasm in children treated in EORTC 58881 trial for acute lymphoblastic malignancies: low incidence of CNS tumours.
Renard M; Suciu S; Bertrand Y; Uyttebroeck A; Ferster A; van der Werff Ten Bosch J; Mazingue F; Plouvier E; Robert A; Boutard P; Millot F; Munzer M; Mechinaud F; Lescoeur B; Baila L; Vandecruys E; Benoit Y; Philippet P;
Pediatr Blood Cancer; 2011 Jul; 57(1):119-25. PubMed ID: 21412967
[TBL] [Abstract][Full Text] [Related]
35. Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia.
Nagafuji K; Miyamoto T; Eto T; Ogawa R; Okumura H; Takase K; Kawano N; Miyazaki Y; Fujisaki T; Wake A; Ohno Y; Kurokawa T; Kamimura T; Takamatsu Y; Yokota S; Akashi K
Eur J Haematol; 2019 Sep; 103(3):164-171. PubMed ID: 31132205
[TBL] [Abstract][Full Text] [Related]
36. DNMT3A mutations and prognostic significance in childhood acute lymphoblastic leukemia.
Li W; Gao C; Cui L; Liu S; Zhao X; Zhang R; Wu M; Zheng H; Deng G; Li Z; Zhang Q
Leuk Lymphoma; 2015 Apr; 56(4):1066-71. PubMed ID: 25242092
[TBL] [Abstract][Full Text] [Related]
37. Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia.
Chang J; Douer D; Aldoss I; Vahdani G; Jeong AR; Ghaznavi Z; Zhang S; Yaghmour G; Lee KJ; Weissman A; Akhtari M
Cancer Med; 2019 Jun; 8(6):2832-2839. PubMed ID: 31016870
[TBL] [Abstract][Full Text] [Related]
38. Progress in the treatment of adults with acute lymphoblastic leukemia.
Larson S; Stock W
Curr Opin Hematol; 2008 Jul; 15(4):400-7. PubMed ID: 18536580
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Young Adults with Acute Lymphoblastic Leukemia.
Kansagra A; Litzow M
Curr Hematol Malig Rep; 2017 Jun; 12(3):187-196. PubMed ID: 28353017
[TBL] [Abstract][Full Text] [Related]
40. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
